TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Update 12/2020: Brilliant work by collaborators in Pakistan, Nigeria and Zambia – despite COVID-19 pandemic, the trial has recruited over 2300 women with moderate and severe anaemia already!
The WOMAN-2 trial investigates Tranexamic Acid (TXA) for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo-controlled trial.
After the success of the WOMAN trial, which showed that TXA reduces premature death for treatment of Postpartum Haemorrhage (PPH) for women in labour by one-third if TXA is administered within 3 hours, the WOMAN-2 trial investigates if we can use TXA to prevent PPH from happening in the first place.
“PPH is responsible for about 100,000 maternal deaths every year, most of which occur in low and middle-income countries.
Source: World Health Organisation (WHO)
Priority diseases and reasons for inclusion
TXA reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots and decreases blood loss in surgery reducing death due to bleeding after trauma.
When given within three hours of birth, TXA reduces deaths due to bleeding in women with PPH. However, for many women, the treatment of PPH is too late to prevent death. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. These women have an increased risk of PPH and suffer more severe outcomes if PPH occurs.
There is an urgent need to identify a safe and effective way to reduce postpartum bleeding in anaemic women.
Interested to learn more?